Anti-Rat Kappa Light Chain In Vivo Antibody - Low Endotoxin
Introducing the Anti-Rat Kappa Light Chain In Vivo Antibody - Low Endotoxin from Assay Genie, a highly specific monoclonal antibody specially designed for in vivo applications. This antibody targets the kappa light chain of immunoglobulins, making it an excellent tool for research in immunology, oncology, and related fields. With its rat IgG2a isotype, it ensures high purity and remarkably low endotoxin levels (<1.0 EU/mg), making it ideal for ELISA, flow cytometry, immunohistochemistry, and additional assays.
It is available in various sizes and formulated in phosphate-buffered saline (PBS) for enhanced stability and performance. Elevate your research with this reliable, high-quality antibody.
The kappa light chain is a component of antibody structure pivotal to antibody diversity and specificity. It is expressed on the surface of B cells and plasma cells, playing a crucial role in the immune response by contributing to antigen recognition and neutralization.
Product Name:
Anti-Rat Kappa Light Chain In Vivo Antibody - Low Endotoxin
Product Code:
IVMB0305
Size:
1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:
MAR 18.5
Protein:
Kappa Light Chain
Product Type:
Monoclonal Antibody
Isotype:
Mouse IgG2a k
Reactivity:
Rat
Applications:
ELISA, FA, In Vivo, WB
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Purity:
≥95% by SDS Page â‹… ≥95% monomer by analytical SEC
Product Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:
ELISA, FA, In Vivo, WB
Reactivity:
Rat
Host Species:
Mouse
Specificity:
MAR 18.5 activity is directed against rat kappa immunoglobulin light chain of both RI-1a and RI-1b allotypes.
Antigen Distribution:
Immunoglobulins consist of heavy chains and light chains. Kappa is a class of light chain and is encoded by the V (variable), J (joining), and C (constant) segments.
Immunogen:
Soluble rat immunoglobulin
Concentration:
≥ 5.0 mg/ml
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:
≥95% by SDS Page â‹… ≥95% monomer by analytical SEC
Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.
MAR 18.5 is a monoclonal antibody directed against rat kappa light chains1. MAR 18.5 was generated by immunizing SJL/J mice with soluble rat immunoglobulin, followed by the creation of a B cell hybridoma line via fusion of immune spleen with P3X63Ag8 myeloma cells. MAR 18.5 hybridoma cells secrete an IgG2a kappa monoclonal antibody that strongly binds to protein A. Additionally, MAR 18.5 antibody binds similarly to Ig of RI-1a and RI-1b allotypes. MAR 18.5 antibody can be used in combination with anti-CD19 and anti-CD22 for in vivo B cell depletion in mice2,3. In a study on Fcgamma receptor-mediated phagocytosis, MAR 18.5 antibody was used as a secondary cross-linking antibody during stimulation of macrophages grown in medium lacking L cell–conditioned medium (LCM) and treated with chilled supernatant from the rat anti-FcgammaR 2.4G2 hybridoma4. Additionally, MAR 18.5 antibody has been used for T cell isolation and complement lysis in combination with J11d.2 (anti-heat-stable Ag), 2.43 (anti-CD8), M5/114 (anti-class II), and 2.4G2 (anti-FcR)5.
